Avanos Medical Inc.
| NYSE: AVNS | Healthcare / Medical Devices & Instruments / USA |
| 28.77 | -0.7300 | -2.47% | Vol 425.91K | 1Y Perf -9.15% |
| Mar 22nd, 2023 15:36 DELAYED |
| BID | 28.75 | ASK | 28.78 | ||
| Open | 29.48 | Previous Close | 29.50 | ||
| Pre-Market | 29.50 | After-Market | - | ||
| - -% | - - |
| Target Price | 28.33 | Analyst Rating | Hold 2.77 | |
| Potential % | -1.80 | Finscreener Ranking | ★★ 45.12 | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★★★ 50.36 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ★★+ 49.26 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 60.93 | Earnings Rating | Sell | |
| Market Cap | 1.34B | Earnings Date | 3rd May 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.11 | |
| Beta | 0.85 |
Today's Price Range 28.7429.58 | 52W Range 19.3234.83 | 5 Year PE Ratio Range -50.8060.00 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 5.85% | ||
| 1 Month | 1.27% | ||
| 3 Months | 10.99% | ||
| 6 Months | 31.76% | ||
| 1 Year | -9.15% | ||
| 3 Years | 39.55% | ||
| 5 Years | -37.23% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -1.09 | |||
ROE last 12 Months | 3.77 | |||
ROA (5Y Avg) | -0.78 | |||
ROA last 12 Months | 2.81 | |||
ROC (5Y Avg) | 1.38 | |||
ROC last 12 Months | 3.21 | |||
Return on invested Capital Q | 1.17 | |||
Return on invested Capital Y | 0.72 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 4.60 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 29.70 | ||||
| 1.00 | ||||
| 2.08 | ||||
| 11.90 | ||||
| 29.40 | ||||
| 2.27 | ||||
| 6.94 | ||||
| 27.17 | ||||
| 1.45B | ||||
| Forward PE | 16.52 | |||
| PEG | -7.79 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.60 | ||||
| 2.90 | ||||
| 0.18 | ||||
| 0.24 | ||||
| 9.60 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 54.10 | ||||
| 9.30 | ||||
| 14.80 | ||||
| -3.90 | ||||
| 5.58 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 602.50M | ||||
| 12.96 | ||||
| 3.71 | ||||
| -6.18 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | 0.48 | 0.60 | 25.00 |
| Q03 2022 | 0.36 | 0.38 | 5.56 |
| Q02 2022 | 0.39 | 0.41 | 5.13 |
| Q01 2022 | 0.24 | 0.26 | 8.33 |
| Q04 2021 | 0.40 | 0.46 | 15.00 |
| Q03 2021 | 0.27 | 0.25 | -7.41 |
| Q02 2021 | 0.23 | 0.21 | -8.70 |
| Q01 2021 | 0.18 | 0.23 | 27.78 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | 0.48 | -2.04 | Negative |
| 12/2022 FY | 1.52 | 0.66 | Positive |
| 3/2023 QR | 0.33 | -13.16 | Negative |
| 12/2023 FY | 1.68 | -2.89 | Negative |
| Next Report Date | 3rd May 2023 |
| Estimated EPS Next Report | 0.28 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 425.91K |
| Shares Outstanding | 46.60K |
| Shares Float | 34.25M |
| Trades Count | 6.07K |
| Dollar Volume | 12.37M |
| Avg. Volume | 315.81K |
| Avg. Weekly Volume | 419.26K |
| Avg. Monthly Volume | 294.24K |
| Avg. Quarterly Volume | 233.92K |
Avanos Medical Inc. (NYSE: AVNS) stock closed at 29.5 per share at the end of the most recent trading day (a 3.36% change compared to the prior day closing price) with a volume of 322.12K shares and market capitalization of 1.34B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 5380 people. Avanos Medical Inc. CEO is Joseph F. Woody.
The one-year performance of Avanos Medical Inc. stock is -9.15%, while year-to-date (YTD) performance is 9.02%. AVNS stock has a five-year performance of -37.23%. Its 52-week range is between 19.32 and 34.83, which gives AVNS stock a 52-week price range ratio of 60.93%
Avanos Medical Inc. currently has a PE ratio of 29.70, a price-to-book (PB) ratio of 1.00, a price-to-sale (PS) ratio of 2.08, a price to cashflow ratio of 11.90, a PEG ratio of 2.32, a ROA of 2.81%, a ROC of 3.21% and a ROE of 3.77%. The company’s profit margin is 5.58%, its EBITDA margin is 14.80%, and its revenue ttm is $602.50 Million , which makes it $12.96 revenue per share.
Of the last four earnings reports from Avanos Medical Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.28 for the next earnings report. Avanos Medical Inc.’s next earnings report date is 03rd May 2023.
The consensus rating of Wall Street analysts for Avanos Medical Inc. is Hold (2.77), with a target price of $28.33, which is -1.80% compared to the current price. The earnings rating for Avanos Medical Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Avanos Medical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Avanos Medical Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.23, ATR14 : 0.88, CCI20 : 130.49, Chaikin Money Flow : 0.06, MACD : -0.24, Money Flow Index : 44.36, ROC : -0.41, RSI : 57.52, STOCH (14,3) : 94.61, STOCH RSI : 1.00, UO : 67.36, Williams %R : -5.39), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Avanos Medical Inc. in the last 12-months were:
Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. The firm operates in one segment, medical devices, which primarily sells products related to pain management, IV Therapy, and respiratory and digestive health. The company divides its Medical Devices segment into two franchises: Pain Management and Chronic Care. Pain Management provides non-opioid products for acute and interventional pain, including cold and compression therapy. Chronic Care aims at addressing digestive and respiratory issues with feeding tubes and catheters. Avanos generates most of its revenue from its Chronic Care franchise and in North America.
CEO: Joseph F. Woody
Telephone: +1 844 428-2667
Address: 5405 Windward Parkway, Alpharetta 30004, GA, US
Number of employees: 5 380
